Bacillus virus phi29

[6][7][8][9] In nature, the Φ29 phage infects Bacillus subtilis, a species of gram-positive, endospore-forming bacteria that is found in soil, as well as the gastrointestinal tracts of various marine and terrestrial organisms, including human beings.

[16][17][18] In the year 2000, a study by Simpson et al. employed cryo-electron microscopy to determine that, in vivo, only a pentamer or smaller polymer could spatially fit in the virus.

[18] Ultimately, single isomorphous replacement with anomalous scattering (SIRAS) crystallography was used to determine that the in vivo structure is a tetramer ring.

[20] Specifically, the functional domains of pRNA bind to the gp16 packaging enzyme and the structural connector molecule to aid in the translocation of DNA through the prohead channel.

[22][23] This allows the initiation of DNA replication to be more accurate by having the polymerase complex check a specific sequence before beginning the elongation process.

[8] This is primarily because RNA nanotechnology is still an emerging field that lacks industrial application and manufacturing optimization of small RNAs.

[8] Nanoparticles need to be stabilized as delivery mechanisms in order to adapt to microenvironments that may result in loss of therapeutic cargo.

[27] Chemotherapy is the only viable current treatment for TNBC because the loss of target receptors inherent to the disease causes cancer cells to resist therapeutic pharmaceuticals.

Bacteriophage Φ29 structural model at atomic resolution [ 1 ]
Schematic drawing of a Φ29 phage virion (cross section and side view).
The replication mechanism of bacteriophage Φ29
Targeting of TNBC molecules by bacteriophage Φ29 pRNA